News | Artificial Intelligence | February 23, 2021

icobrain cva allows the quantitative assessment of tissue perfusion by reporting the volume of core and perfusion lesion by quantifying Tmax abnormality and CBF abnormality together with the mismatch volume and ratio

icobrain cva allows the quantitative assessment of tissue perfusion by reporting the volume of core and perfusion lesion by quantifying Tmax abnormality and CBF abnormality together with the mismatch volume and ratio

February 23, 2021 — icometrix, world leader in imaging artificial intelligence (AI) solutions for people with neurological conditions, announced the addition of icobrain cva, a stroke solution, to the icobrain portfolio. The announcement follows the FDA-clearance and CE-marking of its image processing software for the analysis and communication of the tissue perfusion state on computed tomography (CT) perfusion scans in patients with ischemic stroke. icobrain cva provides physicians with fast, fully automated, and state-of-the-art insights to support treatment decisions in acute ischemic stroke.

Since 2018, treatment guidelines for stroke have expanded the treatment window for mechanical thrombectomy from 6 to 24 hours. Treatment for ischemic stroke is not without risk and requires careful patient selection based on their tissue status. The automated assessment of tissue parameters in an acute clinical setting by icobrain cva will allow more patients to get the right treatment and can improve patient outcomes and care while increasing efficiency.

"With the launch of icobrain cva we address a persisting need in the treatment of acute ischemic stroke. By democratizing advanced CT perfusion analysis for healthcare systems worldwide we take the next step in our mission to become a holistic brain solution provider," said Wim Van Hecke, CEO at icometrix.

"The main challenge of current stroke solutions is correctly identifying the entry point of the injected contrast in the brain. icobrain cva introduces new, patented, deep learning technology into this identification process to achieve a more robust assessment of the infarcted area," explained Dirk Smeets, CTO at icometrix.

icobrain cva is a fully-automated CE-marked and FDA-cleared software solution for the quantitative assessment of tissue perfusion on CT. icobrain cva reports the volume of the core and perfusion lesion by quantifying reduced cerebral blood flow, volume, and transit time. The report includes information on the correctness of the selected arterial input function and the quality of the output. icobrain cva is a cloud-based solution, returning a report and perfusion maps straight into your PACS and e-mail inbox.

For more information: icometrix.com


Related Content

News | Radiology Imaging

April 7, 2026 — Onvida Health and Siemens Healthineers have entered a 10-year Value Partnership¹ designed to bring the ...

Time April 09, 2026
arrow
News

The Society of Nuclear Medicine and Molecular Imaging's (SNMMI) 2026 Annual Meeting will take place May 30–June 2 in Los ...

Time April 07, 2026
arrow
News | Computed Tomography (CT)

April 2, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for True ...

Time April 03, 2026
arrow
News | Ultrasound Imaging

March 30, 2026 — Butterfly Network, Inc. has received clearance from the U.S. Food and Drug Administration (FDA) for a ...

Time April 01, 2026
arrow
News | Computed Tomography (CT)

March 30, 2026 — HCA Healthcare’s Good Samaritan Hospital is the first hospital in the Bay Area to implement Lumina 3D ...

Time April 01, 2026
arrow
News | Radiology Business

March 31, 2026 — Radon Medical Imaging, a medical imaging equipment maintenance and repair services company, has has ...

Time March 31, 2026
arrow
News | Radiology Imaging

March 26, 2026 — GE HealthCare has announced a renewed research collaboration with Stanford Medicine Department of ...

Time March 30, 2026
arrow
News | Cardiac Imaging

March 28, 2026 — When Ashley Perlow felt a sharp pain shoot across her chest and into both wrists, she didn't think it ...

Time March 30, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

March 25, 2026 A Penn Medicine–led team has developed a first‑of‑its‑kind artificial intelligence system that interprets ...

Time March 26, 2026
arrow
News | FDA

March 24, 2026 — MARS Bioimaging, a New Zealand–headquartered medical device company, has received U.S. Food and Drug ...

Time March 25, 2026
arrow
Subscribe Now